SS-31 is a synthetic tetrapeptide engineered to enter mitochondria and bind cardiolipin, the signature phospholipid of the inner mitochondrial membrane, where it is reported to stabilize membrane structure and improve the efficiency of energy production. Under its generic name elamipretide, the molecule received FDA accelerated approval in September 2025 as FORZINITY for Barth syndrome, making it the first FDA-approved mitochondria-targeted therapy; for every other condition it has been studied against, including primary mitochondrial myopathy and heart failure, it remains investigational. The mechanistic account that follows rests largely on preclinical and cell-based work, with human evidence concentrated in that single approved rare-disease indication.
SS-31, known generically as elamipretide, is a mitochondria-targeting tetrapeptide that binds cardiolipin to support energy production, FDA-approved in September 2025 as FORZINITY for Barth syndrome and investigational for all other indications.
The molecule is a water-soluble tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine-Lys-Phe-amide, built from four residues and capped with a C-terminal amide. Two deliberate design choices define it: a D-configuration arginine that resists breakdown by the body's peptidases, and a modified tyrosine whose extra methyl groups tune both its aromatic character and its resistance to oxidation. It belongs to the Szeto-Schiller family developed by Hazel Szeto and Peter Schiller, a series originally explored as opioid-related analogs before its mitochondrial-concentrating property was recognized.
SS-31 is a tetrapeptide of sequence D-Arg-2',6'-dimethyltyrosine-Lys-Phe-amide, carrying a net charge near +3 and a molecular weight of roughly 640 daltons.
Unlike most mitochondria-directed molecules, SS-31 concentrates at the inner mitochondrial membrane without depending on the membrane's voltage. Its aromatic-cationic structure lets it diffuse across cell membranes and accumulate at the inner membrane, with reported enrichment on the order of a thousandfold or more relative to the surrounding cytosol in some experimental systems. That concentrating effect comes from direct association with cardiolipin rather than electrophoretic pull, a distinction that matters most in the injured or depolarized mitochondria that voltage-dependent agents would be shut out of.
| Property | SS-31 | Triphenylphosphonium carriers |
|---|---|---|
| Uptake driver | cardiolipin binding | membrane potential |
| In depolarized mitochondria | still accumulates | uptake collapses |
| Selectivity basis | inner-membrane lipid | electrophoretic charge pull |
SS-31 concentrates at the inner mitochondrial membrane by binding cardiolipin rather than by riding the membrane potential, so it still reaches depolarized mitochondria that voltage-dependent carriers cannot enter.
Cardiolipin is a four-tailed phospholipid found almost exclusively in the inner mitochondrial membrane, where it organizes the respiratory chain into efficient supercomplexes. SS-31 binds it through electrostatic attraction between the peptide's positive charges and cardiolipin's negative head groups, plus hydrophobic contact with the fatty acyl tails, so the peptide sits at the membrane interface rather than sinking into the lipid core. Laboratory work reports that this reversible association stabilizes the curved cristae geometry and shields cytochrome c from turning into a cardiolipin-degrading peroxidase, all without uncoupling respiration under normal conditions.
By binding cardiolipin at the inner membrane, SS-31 is reported to stabilize cristae architecture and block cytochrome c from acting as a cardiolipin-degrading peroxidase, while leaving normal respiration undisturbed.
The connection between SS-31 and energy output runs through the organization of the respiratory chain. When cardiolipin is intact and properly bound, the electron transport complexes and ATP synthase assemble into supercomplexes that pass electrons efficiently, and preclinical work describes SS-31 as helping maintain those assemblies rather than forcing raw respiration upward. The reported gain is in coupling efficiency, meaning more of the fuel burned is captured as usable ATP; experimental models of fatigued or ischemic muscle have shown faster phosphocreatine recovery, though these remain investigational findings rather than proven clinical outcomes.
By preserving cardiolipin-dependent supercomplex assembly, SS-31 is reported to improve the coupling efficiency of the electron transport chain, capturing more burned fuel as ATP rather than forcing respiration higher.
Mitochondria are the main cellular source of reactive oxygen species, formed when electrons escape the respiratory chain, especially at complexes I and III, and react with oxygen to make superoxide and related radicals. The research describes SS-31 as lowering this output primarily at the source, by keeping the respiratory complexes tightly assembled so fewer electrons leak, rather than by mopping up radicals after they form. A secondary, more conventional antioxidant role from the dimethyltyrosine residue has also been reported, but the dominant effect is the upstream reduction in leak.
SS-31 is reported to cut mitochondrial reactive oxygen species mainly at their origin, reducing electron leak from the respiratory chain rather than scavenging radicals after they form.
The same molecule appears in the literature under several names, each tied to a stage of its history. SS-31 is the original laboratory designation, its initials honoring inventors Hazel Szeto and Peter Schiller, while MTP-131 and the program name Bendavia mark its move toward pharmaceutical development and earlier heart-focused work. Elamipretide is the international nonproprietary name used in recent trials, publications, and agency filings, which means anyone surveying the literature can meet apparent duplicate results that are simply the same peptide under different labels.
| Name | Origin | Where it appears |
|---|---|---|
| SS-31 | Szeto-Schiller series designation | basic-science, mechanistic literature |
| MTP-131 | pharmaceutical development code | earlier-stage reports |
| Bendavia | early heart-program name | ischemia-reperfusion studies |
| Elamipretide | international nonproprietary name | recent trials, filings, FORZINITY approval |
SS-31, MTP-131, Bendavia, and elamipretide all name one chemical entity, with elamipretide the standardized generic term now used in trials and regulatory filings.
The regulatory picture splits cleanly along one line. Under the name elamipretide, the compound received FDA accelerated approval in September 2025 as FORZINITY for Barth syndrome in patients weighing at least 30 kilograms, its first and only approved indication; for every other use it remains an investigational drug not approved by the FDA or other major regulators. The Barth approval rests on an improvement in knee-extension muscle strength that the FDA considers reasonably likely to predict patient benefit, and it carries a required post-approval confirmatory trial.
SS-31 (elamipretide) holds a single FDA accelerated approval, granted September 2025 as FORZINITY for Barth syndrome; all other uses remain investigational and unapproved.
Because SS-31 acts on mitochondrial energy production, a mechanism shared by nearly every cell, its investigational reach spans a broad set of conditions unified by tissues that depend heavily on mitochondria. The most prominent target has been primary mitochondrial myopathy, a group of inherited disorders in which defective mitochondria leave skeletal muscle chronically energy-starved. Cardiac disease, retinal disease, and kidney injury round out the list, each involving mitochondria-dense tissue, though the peptide has not yet proven itself for any single indication outside Barth syndrome.
SS-31 has been studied across primary mitochondrial myopathy, cardiac disease, retinal disorders, and kidney injury, all tissues with high mitochondrial density, yet it has proven itself only in Barth syndrome to date.
In clinical work the peptide has mainly been delivered as a once-daily subcutaneous injection, with intravenous infusion used in some earlier acute-care studies around heart-attack reperfusion. Oral dosing is impractical because peptides of this kind absorb poorly from the gut, so parenteral routes remain standard even with the D-arginine protection. Reported pharmacokinetics describe reasonable systemic exposure after subcutaneous dosing with pronounced uptake into mitochondria-rich organs, consistent with the peptide's strong tissue partitioning rather than confinement to plasma.
SS-31 is administered parenterally, most often as a once-daily subcutaneous injection, and its D-arginine and amidated terminus give it strong peptidase resistance and pronounced uptake into mitochondria-rich tissue.
Educational use only. This article describes what the published scientific and clinical literature reports about SS-31. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
